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Abstract
Background: Cervical cancer continues to be an important worldwide health problem for women. Up to 35% of
patients who are diagnosed with and appropriately treated for cervical cancer will recur and treatment results are
poor for recurrent disease. Given these sobering statistics, development of novel therapies for cervical cancer
remains a high priority. We evaluated the expression of Tissue Factor (TF) in cervical cancer and the potential of hI-
con1, an antibody-like-molecule targeted against TF, as a novel form of immunotherapy against multiple primary
cervical carcinoma cell lines with squamous- and adenocarcinoma histology.
Methods: Because TF is a transmembrane receptor for coagulation factor VII/VIIa (fVII), in this study we evaluated
the in vitro expression of TF in cervical carcinoma cell lines by immunohistochemistry (IHC), real time-PCR (qRT-
PCR) and flow cytometry. Sensitivity to hI-con1-dependent cell-mediated-cytotoxicity (IDCC) was evaluated in 5-hrs-
51chromium-release-assays against cervical cancer cell lines in vitro.
Results: Cytoplasmic and/or membrane TF expression was observed in 8 out of 8 (100%) of the tumor tissues
tested by IHC and in 100% (11 out of 11) of the cervical carcinoma cell lines tested by real-time-PCR and flow
cytometry but not in normal cervical keratinocytes (p = 0.0023 qRT-PCR; p = 0.0042 flow cytometry). All primary
cervical cancer cell lines tested overexpressing TF, regardless of their histology, were highly sensitive to IDCC
(mean killing ± SD, 56.2% ± 15.9%, range, 32.4%-76.9%, p < 0.001), while negligible cytotoxicity was seen in the
absence of hI-con1 or in the presence of rituximab-control-antibody. Low doses of interleukin-2 further increased
the cytotoxic effect induced by hI-con1 (p = 0.025) while human serum did not significantly decrease IDCC against
cervical cancer cell lines (p = 0.597).
Conclusions: TF is highly expressed in squamous and adenocarcinoma of the uterine cervix. hI-con1 induces
strong cytotoxicity against primary cervical cancer cell lines overexpressing TF and may represent a novel
therapeutic agent for the treatment of cervical cancer refractory to standard treatment modalities.
* Correspondence: alessandro.santin@yale.edu
1Department of Obstetrics, Gynecology & Reproductive Sciences, Yale
University School of Medicine, 333 Cedar street, New Haven (06519), CT, USA
Full list of author information is available at the end of the article
Cocco et al. BMC Cancer 2011, 11:263
http://www.biomedcentral.com/1471-2407/11/263
© 2011 Cocco et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Background
Despite aggressive screening programs, cervical cancer
remains an important public health issue. In the United
States about 12,200 new cases of cervical cancer as well
as 4,210 deaths from cervical cancer are estimated for
2010 [1]. Although cervical cancer is, to a large extent, a
preventable disease, it remains an important health pro-
blem for women, especially in underserved and minority
groups in industrially developed nations and women in
developing countries without established screening pro-
grams. While early stage cervical cancer can be cured by
radical surgery or radiotherapy with equal effectiveness
[2], pelvic radiation represents the standard therapy for
the treatment of locally advanced disease. Despite tech-
nological advances, however, up to 35% of patients over-
all will develop recurrent disease, for which treatment
results are poor [3]. A deeper understanding of the
molecular basis of cervical cancer has the potential to
significantly refine the diagnosis and management of
these tumors and may eventually lead to the develop-
ment of novel, more specific, and more effective treat-
ments for prevention of disease progression following
first-line therapy.
Angiogenesis, the formation of new vessels from pre-
existing vasculature, is known to represent a critical step
in the development, progression and metastatic process
of human solid tumors. Tissue factor (TF), a transmem-
brane receptor for coagulation factor VII/VIIa (fVII), is
aberrantly expressed in human cancers and on endothe-
lial cells within the tumor vasculature [4,5]. Importantly,
tumor cells characterized by a high production of TF
and vascular endothelial growth factor (VEGF), a crucial
initiator of angiogenesis, are known to generate solid
tumors characterized by intense vascularity and highly
aggressive behavior [6]. Consistent with this view, sev-
eral studies have shown that VEGF is overexpressed and
secreted in a variety of human tumors including cervical
carcinomas [7] and an elevated expression of VEGF is
correlated clinically with cervical cancer metastasis and
poor patient survival [8]. While a direct regulation of
VEGF expression in human tumor cells by the cytoplas-
mic tail of TF has been previously demonstrated [7],
recent studies indicate that type-2 proteinase activated
receptor (PAR-2) is intimately involved in TF-mediated
signaling and angiogenesis [9]. These data suggest a
potential direct role for TF in tumor growth [9].
hI-con1™ (Iconic Therapeutics, Inc.; Atlanta, GA) is a
previously characterized immuno-conjugate molecule
developed against TF [10-12]. It is composed of two
identical protein chains consisting of human fVII as the
targeting domain fused to human IgG1 Fc as the effector
domain; the two chains are held together by the disul-
fide bonds normally present in IgG. The hI-con1 is
designed to bind to TF with far higher affinity and spe-
cificity than can be achieved with an anti-TF antibody.
Indeed, the hI-con1 has several important advantages
over monoclonal antibodies for targeting TF including:
1) The Kd for fVII domain binding to TF is about 10
-12
M [13], in contrast to anti-TF antibodies that have a Kd
in the range of 10
-8 to 10
-9 M for TF [14], and 2) the
hI-con1 is produced by recombinant DNA technology,
allowing a completely human hI-con1 to be made for
future clinical trials. Because binding of fVII to TF
could induce disseminated intravascular coagulation, a
potentially lethal vascular disease, an amino acid substi-
tution was introduced into the fVII domain of the hI-
con1 (Lys 341 to Ala) to inhibit initiation of the coagu-
lation pathway without reducing the strong affinity for
TF [10,15]. The human Fc domain of the hI-con1 may
thus potentially activate powerful cytolytic responses
mediated by antibody-dependent cell-mediated cytotoxi-
city (ADCC) against both TF-expressing tumor cells and
tumor vascular endothelial cells that bind the hI-con1
molecule.
To our knowledge, no studies have specifically
described the expression of tissue factor in cervical can-
cer. Therefore, in this report we investigated the expres-
sion of TF at mRNA and protein levels in multiple
primary cervical tumor cell lines and evaluated for the
first time the in vitro potential of hI-con1 as a novel
immunotherapeutic agent against biologically aggressive
cervical cancer cell lines overexpressing TF.
Methods
Establishment of Primary Cervical Cancer Cell Lines
Primary cervical tumor cell lines from eleven patients
harboring cervical cancer were obtained from fresh
tumor biopsies collected at the time of primary surgery
or surgery for cancer recurrence under approval of the
Institutional Review Board. Tumors were staged accord-
ing to the International Federation of Gynecologists and
Obstetricians staging system. Source-patient characteris-
tics of these eleven cell lines are described in Table 1.
Human papillomavirus (HPV) typing of these specimens
was performed by PCR using sequence-specific primers
for HPV 16 and 18 against E7 oncoprotein (Integrated
DNA Technologies, Coralville, IA), as previously
described [16].
Quantitative real-time PCR in Primary Cell Lines
RNA isolation from 11 primary cervical cancer cell lines
(Table 1) was performed using TRIzol Reagent (Invitro-
gen, Carlsbad, CA) according to the manufacturer’s
instructions. Quantitative PCR was done with a 7500
Real Time PCR System using the manufacturer’s recom-
mended protocol (Applied Biosystems, Foster City, CA)
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tion was run in duplicate. Briefly, 5 μgo ft o t a lR N A
from each sample was reverse transcribed using Super-
Script III first-strand cDNA synthesis (Invitrogen). Five
μL of reverse transcribed RNA samples (from 500 μLo f
total volume) were amplified by using the TaqMan Uni-
versal PCR Master Mix (Applied Biosystems) to produce
PCR products specific for TF. The primers and probe
for TF were obtained from Applied Biosystems (Assay
ID Hs01076032_m1). The comparative threshold cycle
(CT) method (Applied Biosystems) was used to deter-
mine gene expression in each sample relative to the
value observed in the lowest nonmalignant cervical kera-
tinocyte cell sample, using glyceraldehyde-3-phosphate
dehydrogenase (Assay ID Hs99999905_m1) RNA as
internal control.
TF immunostaining of Formalin-fixed Cervical
Cancer Tissues
Formalin-fixed, paraffin-embedded tissue blocks
obtained from 5 stage IB patients, 1 stage IIA and 2
stage III B patients (i.e., 4 squamous- and 4 adenocarci-
nomas) were retrieved from a separate set of 8 patients
from the surgical pathology files at Yale University. All
tumor samples and eight normal cervical tissue speci-
mens used as controls were reviewed by a surgical
pathologist (NB). The level of TF expression was then
evaluated on the most representative block by standard
immunohistochemical (IHC) staining. For immunohisto-
chemistry, 4 μm sections were cut from the formalin-
fixed paraffin-embedded blocks. Following deparaffiniza-
tion and rehydration, endogenous peroxidase was
blocked in 3% H2O2.S t e a ma n dh i g hp H( p H9 )w e r e
used for antigen retrieval. The slides were then incu-
bated overnight at 4°C with monoclonal anti-TF anti-
body (No.4509, 1:10 dilution, American Diagnostica,
Stamford, CT). EnVisionTM system (Dako, Carpinteria,
CA) was used for secondary detection and the reactions
were visualized with diaminobenzidine. Appropriate
positive and negative controls were used with each case.
Both cytoplasmic and membranous immunoreactivity
was considered positive. Immunostaining was assessed
using a semi-quantitative scor i n gs y s t e m ,a sf o l l o w s :0 ,
negative (0% to 5% staining); 1+, weakly positive (10% to
20%); 2+, moderately positive (20% to 50%); 3+ and 4+,
strongly positive (50% to 75% and over 75%, respec-
tively), as previously described [17].
Flow Cytometry
Clinical grade hI-con1 was produced for Iconic Thera-
peutics Inc. (Atlanta, GA) by Laureate Pharma, (Prince-
ton, NJ) by cultivation of BHK cells transfected with a
vector containing the gene sequence originally described
by Hu and Garen [10-12]. The protein was purified by a
series of chromatographic steps to a purity adequate for
clinical use, formulated in 15 mM HEPES, 150 mM
NaCl, 5 mM CaCl2, 25 mM arginine, 0.01% Tween 80,
pH 7.4 buffer and sterile-filtered. It was provided in ali-
quots of 80 μL at a stock concentration of 350 μg/ml
which were used for our flow cytometry and hI-con1-
dependent cell-mediated cytotoxicity (IDCC) studies.
Briefly, cervical cancer cell lines and phytohemagglutinin
(PHA)-stimulated control peripheral blood lymphocytes
(PBL) were stained with hI-con1 at a concentration of
30 μg/ml for 30 minutes on ice or with a commercially
available FITC-conjugated mouse anti-human TF immu-
noglobulin (i.e., positive control, BioSource Interna-
tional, Camarillo, CA). After hI-con1 staining, cells were
washed twice with the same buffer and secondary
mouse-anti-human antibody (IgG1-FITC, catalog #
F0767 Sigma Aldrich, S. Louis, MO) was added for a
further 30 minutes. Analysis was conducted with a
FACSCalibur instrument using Cell Quest software
(Becton Dickinson, Franklin Lakes, NJ).
Tests for IDCC
As t a n d a r d5 - h o u r sc h r o m i u m(
51Cr) release assay was
performed to measure the cytotoxic reactivity of Ficoll-
Hypaque-separated PBL from several healthy donors in
combination with hI-con1 against cervical cancer cell
Table 1 Patient characteristics from which the 11 primary
cancer cell lines were established
Cell line Age
(years)
Race FIGO
Stage
Grade Histopathology
ADX-1 ARK-
1
25 C* IB G3 Adenocarcinoma
ADX-2 ARK-
2
33 C IB G3 Adenosquamous
ADX-3 ARK-
3
33 AA** IB G3 Adenosquamous
ADX-4 ARK-
4
46 C IB G2/G3 Adenocarcinoma
CVX-1 ARK-
1
35 AA IB G3 Squamous
CVX-2 ARK-
2
40 C Recurrence G3 Squamous
CVX-3 ARK-
3
70 C IB G3 Squamous
CVX-4 ARK-
4
40 C IB G3 Squamous
CVX-5 ARK-
5
22 C IB G3 Squamous
CVX-6 ARK-
6
29 C IB G3 Squamous
CVX-7 ARK-
7
42 C Recurrence G3 Squamous
^FIGO, International Federation of Gynecology and Obstetrics
*C, Caucasian;
**AA, African-American
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51Cr from the target cells was mea-
sured as previously described [17] as evidence of tumor
cell lysis after exposure of tumor cells to various con-
centrations of hI-con1 (ranging from 1 to 80 μg/ml) and
different target/effector cells ratios. Controls included
the incubation of target cells alone or with PBL or
monoclonal antibody (mAb) separately. The chimeric
anti-CD20 mAb rituximab (Rituxan
®; Genentech) was
used as control in all bioassays. IDCC was calculated as
the percentage of killing of target cells observed with
mAb plus effector cells as compared with
51Cr release
from target cells incubated alone.
IL-2 Enhancement of IDCC
To investigate the effect of interleukin-2 (IL-2) on
IDCC, effector PBL were incubated for 5 hours at 37°C
at a final concentration of IL-2 (Aldesleukin; Chiron
Therapeutics, Emeryville, CA) ranging from 50 to 100
IU/ml in 96-well microtiter plates. Target cells were pri-
mary cervical cancer cell lines exposed to hI-con1 (con-
centrations ranging from 1 to 80 μg/ml), whereas
controls included the incubation of target cells alone or
with PBL in the presence or absence of IL-2 or mAb,
respectively. Rituximab was used as a control mAb.
IDCC was calculated as the percentage of killing of tar-
get cells observed with mAb plus effector PBL, as com-
pared with target cells incubated alone. Each experiment
was performed with PBL collected from multiple normal
donors, with results from a representative donor
presented.
Test for complement-mediated target cell lysis and g-
globulin inhibition
A standard five-hour chromium (
51Cr) release assay
identical to the previous IDCC assays was used, except
that human serum in a dilution of 1:2 was added to the
effector cells. This human serum was used as a source
of complement to test for complement-mediated target
cell lysis. To test for the possible inhibition of IDCC
against a chemoresistant squamous cervical cancer cell
line by physiological human serum concentrations of g-
globulin, human serum was diluted 1:2 before being
added in the presence or absence of effector PBL.
Experiments were also performed using heat-inactivated
human serum (56°C for 60 minutes; diluted 1:2) in the
presence of effector PBL. Controls included the incuba-
tion of target cells alone or with either PBL or mAb
separately. Rituxan was used as a control mAb.
Statistical Analysis
For qRT-PCR data, the right-skewing was removed by
taking copy-number ratios relative to the lowest-expres-
sing normal cervical keratinocyte sample ("relative copy
numbers”), log2-transforming them to ΔCTs, and
comparing the results via unequal-variance t-test for dif-
ferences between cervical cancer cells versus normal
cervical keratinocytes. Group means with 95% confi-
dence intervals (CI) were calculated by computing them
on the ΔCTs and then reverse-transforming the results
to obtain means (95% CI) of relative copy numbers. Dif-
ferences in TF expression by IHC and flow cytometry
were analyzed by the unpaired t-test. Kruskal-Wallis test
and chi-square analysis were used to evaluate differences
in hI-con1-dependent cell-mediated cytotoxicity levels in
primary tumor cell lines. Statistical analysis was
performed using SPSS version 17 (SPSS, Chicago, IL). A
p-value of < 0.05 was considered statistically significant.
Results
Tissue Factor expression by qRT-PCR in primary cell lines
A total of eleven primary cervical cancer cell lines
including 7 squamous cervical tumors, 2 cervical adeno-
carcinomas and 2 adenosquamous tumors were available
for this study (Table 1). All primary cervical cancer cell
lines were found to harbor HPV 16 or 18 genotypes
(data not shown). With the exception of CVX-1 ARK-1
and CVX-7 ARK-7 cervical cancer cell lines, which were
derived from biopsies obtained from recurrent carci-
noma sites (i.e., a vaginal recurrence, CVX-1 ARK-1)
and a metastatic site of disease (CVX-7 ARK-7, i.e.,
lymph node), all other cell lines were established from
biopsies collected at the time of surgery from the pri-
mary site of disease (i.e., cervix uteri, Table 1). The
mean ± standard error (minimum-maximum) copy
number in tumor samples was 224.8 ± 39.4 (range: 44-
613) versus 0.5 (range: 0.02-1) in normal cells (p =
0.023). Of the eleven tumors tested, nine showed a high
mRNA copy number (i.e., above 100 copies) (Table 2).
Squamous tumor cell lines were found to express signif-
icantly higher level of TF (mean ± SE = 297.2 ± 51)
Table 2 Tissue Factor expression by qRT-PCR in primary
squamous and adenocarcinoma cervical cancer cell lines
Cell line qRT-PCR
mRNA copy #
ADX-1 ARK-1 46.7
ADX-2 ARK-2 156.5
ADX-3 ARK-3 44.2
ADX-4 ARK-4 289.7
CVX-1 ARK-1 382.1
CVX-2 ARK-2 138.3
CVX-3 ARK-3 137.2
CVX-4 ARK-4 109.6
CVX-5 ARK-5 613.9
CVX-6 ARK-6 123.9
CVX-7 ARK-7 480.6
*qRT-PCR, quantitative Real-time Polymerase Chain Reaction.
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quamous tumor cell lines (mean ± SE = 134.2 ± 37.9) (p
= 0.037, Table 2). Of interest, both tumor cell lines (i.e.,
CVX-1 ARK-1 and CVX-7 ARK-7) established from
recurrent/metastatic cervical tumors were found to
express high levels of TF mRNA copy numbers (i.e., 382
and 480, respectively, Table 2).
Tissue Factor expression by IHC in Cervical Carcinoma
samples
We performed immunohistochemical analysis of TF
protein expression on formalin-fixed tumor tissues from
8 paraffin-embedded cervical cancer specimens includ-
ing 4 squamous- and 4 adenocarcinomas. As representa-
tively shown in Figure 1, we found TF expression in 4
out of 4 (100%) of the squamous carcinomas (i.e., one 4
+, two 2+, and one 1+) and 4 out of 4 (100%) of the
adenocarcinomas (i.e., one 3+, one 2+, and two 1+). The
cervical cancer samples showed either membrane and/or
cytoplasmic immunoreactivity for TF while the non-neo-
plastic cervical squamous epithelium and normal cervi-
cal glands were found consistently negative for TF
expression (Figure 1).
Tissue Factor expression by flow cytometry in primary
cervical carcinoma cell lines
Surface TF receptor expression was evaluated by FACS
analysis on all eleven primary cervical cancer cell lines
using hI-con1 and an anti-human TF control mAb. As
negative controls, several PHA-stimulated PBL estab-
lished from healthy donors or the same cervical cancer
patients from which the tumor cell lines had been estab-
lished were also studied. Reactivity against TF was found
by flow cytometry in all cervical cancer cell lines tested,
with ADX-1 ARK-1 and ADX-3 ARK-3 showing lower
expression levels when compared to all the remaining
cells lines (Figure 2 and data not shown). Mean fluores-
cence intensity (MFI) for TF ranged from 61.3 to 106.7
(mean ± SE = 83.8 ± 7.7) in cervical tumor cell lines
versus a MFI ± SE of 35.01 ± 7.5 in the PHA-stimulated
PBL populations used as negative controls (Figure 2,
p = 0.0042).
Cervical tumors overexpressing TF are sensitive to hI-
con1-dependent cell mediated cytotoxicity (IDCC)
Four cervical cancer cell lines, ADX-1 ARK-1 and
CVX-2 ARK-2 (established from biopsies obtained from
a primary adenocarcinoma and a squamous tumor,
respectively), and CVX-1 ARK-1 and CVX-7 ARK-7
(established from recurrent squamous cervical carcino-
mas), were tested for their sensitivity to natural killer
cell (NK) cytotoxicity when challenged with heterolo-
gous PBL, collected from several healthy donors, in
standard 5-hours
51Cr release assay. All primary cervical
cancer cell lines were consistently found to be resistant
to NK-mediated cytotoxicity when combined with PBL
at effector to target (E:T) ratios of 25:1 and 50:1 (range
Figure 1 Representative IHC of TF in squamous- and
adenocarcinoma specimens versus normal cervical control
tissues. Upper left panel: normal ectocervical squamous epithelium
negative for TF. Lower left panel: cervical squamous cell carcinoma
showing high expression of TF. Upper right panel: normal cervical
glands negative for TF. Lower right panel: cervical adenocarcinoma
showing high expression of TF. Original magnification: 200×.
Figure 2 Representative TF expression by flow cytometry of
control PBL (negative control) and CVX-1 ARK-1, CVX-2 ARK-2
and ADX-1 ARK-1 primary cervical cell lines. Isotype (solid black);
hI-con1 (dashed line).
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Page 5 of 10of cytotoxicity: 0.5 - 17.6% with all E:T ratios). Similarly,
primary cervical cancer cell lines incubated with rituxi-
mab (2.5 μg/ml) control antibody displayed no signifi-
cant cytotoxicity (range: 0.5% - 13.03%). In contrast, as
representatively shown in Figure 3, we found all cervical
tumor cell lines tested expressing TF, regardless of their
squamous or adenocarcinoma histology or their primary
versus metastatic/recurrent tumor sites of origin, to be
highly sensitive to IDCC (mean ± SD: 56.2% ± 15.9%,
range: 32.4% - 76.9% for the E:T ratio 50:1, Figure 3, p <
0.001). Importantly, high levels of hI-con1-induced cyto-
toxicity were also detected against CVX-1 ARK-1, a
squamous cervical cancer cell line established from a
patient experiencing recurrent disease after chemo-
radiation resistant tumor (Figure 3) and CVX-7 ARK-7,
a tumor established from a metastatic recurrent site of
disease (data not shown). Negligible cytotoxicity was
detected against PHA-stimulated PBL controls incubated
with hI-con1 (mean ± SD, 4.8% ± 1.8% for the E:T ratio
50:1; Figure 3).
IL-2 Enhancement of IDCC against cervical tumors
To investigate the effect of low doses of IL-2 in combi-
nation with hI-con1 (30 μg/ml) on IDCC against pri-
mary cervical cancer cell lines, PBL from healthy donors
were incubated for 5 hours in the presence of 50 to 100
Figure 3 Representative cytotoxicity experiments using hI-con1 against control PBL and CVX-1 ARK-1, CVX-2 ARK-2 and ADX-1 ARK-1
primary cervical cell lines. Negligible cytotoxicity was detected in the absence of hI-con1 or in the presence of rituximab control mAb.
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Page 6 of 10IU/ml of IL-2. As representatively shown in Figure 4 for
CVX-2 ARK-2, in multiple experiments in all cervical
tumors tested in the presence of IL-2 (i.e., ADX-1 ARK-
1, CVX-1 ARK-1 and CVX-2 ARK-2), IDCC was consis-
tently increased in the presence of low doses of the
cytokine. Administration of 50 to 100 IU/ml of IL-2 to
the effector PBL at the start o ft h ea s s a yi n c r e a s e dt h e
cytotoxic activity against primary cervical cancer cell
lines overexpressing TF compared with the use of
hI-con1 alone (Figure 4, p = 0.025) whereas no signifi-
cant increase in cytotoxicity was detected after 5 hours
of IL-2 treatment in the absence of hI-con1 or in the
presence of rituximab control mAb (Figure 4). These
results demonstrate that low levels of IL-2 may enhance
hI-con1-mediated-cell-cytotoxicity in primary cervical
cancer cell lines in vitro.
Effect of complement and physiological concentrations of
IgG on hI-con1-mediated IDCC
In order to evaluate the effect of complement on the hI-
con1-mediated IDCC as well as the potential inhibition
of hI-con1 cytotoxic activity by physiological human
serum g-globulin concentrations, human serum diluted
1:2 (with and without heat inactivation) was added to a
representative squamous cervical cancer cell line (CVX-
7 ARK-7) during standard 5-hours
51Cr release assays.
The addition of untreated or heat inactivated human
serum diluted 1:2 did not significantly alter the cytotoxic
effect of hI-con1 against CVX-7 ARK-7 cell line when
compared to hI-con1-mediated killing without serum (p
= 0.597, Figure 5).
Discussion
The management of disseminated carcinoma of the cer-
vix that is no longer amenable to control with surgery
or radiation therapy has not improved significantly with
the advent of modern chemotherapy [2,3]. The one-year
survival rate remains between 10 and 15 percent [2,3].
Thus, the development of novel, target-specific and
effective modalities against cervical cancer refractory to
standard treatments remains desperately needed.
We have evaluated Tissue Factor (TF) expression by
qRT-PCR, IHC and flow cytometry in cervical tissue
samples and multiple primary cervical cancer cell lines
with squamous- and adenocarcinoma histology, some of
which were derived from recurrent chemo-radiation
resistant tumors. In addition, we have tested the in vitro
activity of hI-con1, a previously characterized immuno-
conjugate molecule developed against TF [10-12], as a
novel therapy against multiple primary cervical cancer
Figure 4 Representative effect of low doses of interleukin-2 (IL-
2) in combination with hI-con1 (30 μg/ml) on ADCC against
CVX-2 ARK-2 primary cell line (Effectors to target ratio 50:1
and 25: 1). PBL from healthy donors were incubated for 5 hours in
the presence of 100 IU/ml of IL-2. hI-con1-DCC was significantly
increased in the presence of low doses of IL-2. No significant
increase in cytotoxicity was detected after 5-h IL-2 treatment in the
absence of hI-con1 or in the presence of the rituximab isotype
control mAb.
Figure 5 Cytotoxicity experiments adding human serum to hI-
con1 (30 μg/ml) against one representative primary cervical
cancer cell line overexpressing TF (i.e., CVX-7 ARK-7: effectors
to target ratio 50:1 and 25:1). Cervical cancer cells were
challenged by diluted (1:2) serum (with or without heat inactivation)
added in the presence of the effector cells and hI-con1 in standard
5-h
51Cr release assays. Addition of treated or untreated human
serum (diluted 1:2) to PBL in the presence of hI-con1 did not
significantly change hI-con1-mediated cytotoxicity against CVX-7
ARK-7 (p = 0.597).
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carcinoma cell lines to overexpress TF when compared
to normal cervical keratinocytes. We speculate that TF
expression may be a common and important event in
malignant transformation of the cervix into biologically
aggressive squamous and adenocarcinoma cervical can-
cers. Furthermore, both cell lines available to this study
established from recurrent/metastatic tumors were
found to express extremely high levels of TF. These
data are consistent with previous reports in other
human solid tumors showing that a high production of
TF and vascular endothelial growth factor (VEGF), gen-
erate solid tumors characterized by highly aggressive
biologic behavior [6]. In this regard, TF is known to be
involved in pathological angiogenesis and is abnormally
overexpressed in multiple human tumors and in tumor
vascular endothelial cells but not on normal quiescent
vascular endothelial cells [5,6]. Although TF, as a cell
surface receptor, is physiologically expressed on extra-
vascular cells of many organs and in the adventitial
layer of the blood vessel wall, it is sequestered by coagu-
lation factor VII (fVII), a natural ligand for TF, at these
sites by the tight endothelial cell layer of the normal
vasculature [5,6]. Thus, pathologically expressed TF may
provide a target for the development of novel cancer
therapies effective not only against tumor cells but also
tumor blood vessels [10-12,18].
To our knowledge, our results are the first to describe
self-production of TF-coagulation factor VII complex by
primary cervical cancer cell lines. These data are how-
ever consistent with multiple previous reports demon-
strating an association between cervical cancer and
deep-vein thrombosis and/or pulmonary thromboembo-
lism (i.e., Trousseau syndrome) [19-22], a pathologic
state previously reported to be associated with TF over-
expression [23]. Importantly, primary cervical cancer
cell lines overexpressing TF, regardless of their histology
or chemo-radiation therapy resistance, were found to be
highly sensitive to hI-con1-mediated cytotoxicity in vitro.
TF is known to play an important role in tumor meta-
static process, possibly by inducing the coating of the
tumor cell with fibrin that would trap the cells in the
microvasculature, thereby aiding metastases [24-26].
Recently, however, a possible direct role for TF in
tumor growth has also been suggested by studies show-
ing a dramatically reduced tumor growth in mice where
a selective reduction in TF was achieved using small
interfering RNA [26]. Of great interest, in these studies,
the reduction of TF expression did not affect growth of
the tumor cells in vitro, suggesting that TF-mediated
enhancement of tumor growth requires a factor present
in vivo that is not present when cells are grown in vitro
[26]. A potential candidate to explain these findings is
therefore fVIIa, which would form a TF:fVIIa complex
on the surface of tumor cells in vivo leading to activa-
tion of type-2 proteinase activated receptor (PAR2)
dependent signaling [9]. These findings combined with
our results suggest that TF overexpression may poten-
tially provide an additional growth advantage to biologi-
cally aggressive cervical cancers in vivo.
The potential cytotoxic activity of hI-con1 against
human melanoma and prostate tumor cells has pre-
viously been demonstrated by Hu et al. [10-12]. In a
recent study we extended their results by evaluating the
cytotoxic potential of hI-con1 against multiple high
grade, biologically aggressive, Type II endometrial can-
cer cell lines [17]. We found all endometrial carcinomas
that showed high TF expression, regardless of their high
or low HER2/neu expression, were highly susceptible to
IDCC in the presence of effector cells [17]. In the cur-
rent study we expanded our research work with hI-con1
to multiple primary cervical carcinoma cell lines with
squamous and adenocarcinoma histology. It is worth
noting that although these cell lines were resistant to
natural killer cytotoxic activity, IDCC resulted in killing
of up to 50% of tumor cells in 5-hour
51Cr release
assays. Taken together, these in vitro results strongly
suggest that TF may provide a novel target for the treat-
ment of resistant/residual cervical disease and the
destruction of their tumor vasculature that should result
in hI-con1-induced lysis of tumor cells as well as tumor
endothelial cells in vivo. Consistent with this hypothesis
and the central role of angiogenesis in cervical cancer
development and progression, bevacizumab, a huma-
nized antibody able to bind and inactivate VEGF, has
been recently reported to shrink cervical tumors and
delay progression without appreciable toxicity. On the
basis of these encouraging results, bevacizumab is cur-
rently being studied in a Gynecologic Oncology Group
(GOG) phase III trial [27].
For effective cytotoxicity, the effector cells must be
able to interact with the immune-conjugate at the target
site in vivo, even in the presence of high concentrations
of human IgG. In this study we showed that hI-con1-
dependent cytotoxicity against cervical cancer cell lines
was not inhibited by high concentrations (up to 50%) of
human serum. These data, therefore, suggest that in the
presence of effector PBL, human serum may not signifi-
cantly decrease IDCC against cervical cancer cell lines.
Moreover, these results indicate that the binding of hI-
con1 to the Fc receptor on mononuclear effector cells is
likely to occur in vivo.
The degree of ADCC in vitro and in vivo is known to
be mainly dependent on the number and function of
NK cells [28]. NK cells are considered to be the best
suited lymphocytes for ADCC because they carry FcgRIII
receptors, which are activator molecules, and not
FcgRIIb receptors, which inhibit ADCC [29]. NK cells
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Page 8 of 10also carry receptors for interleukin-2 (IL-2), a cytokine
which induces expansion of the NK cell population and
enhances their function [29-31]. Therefore, low dose IL-
2 administered in the outpatient setting has been pre-
viously used to enhance cancer patients’ immune
response to monoclonal antibodies with little toxicity
[30,31]. These findings are particularly interesting
because in previous studies we have found that a major
barrier to the successful development of therapeutic
immunization of advanced cervical cancer patients har-
boring disease refractory to radiation and chemotherapy
was represented by a profound state of immunosuppres-
sion present in the majority of these patients [32]. This
anergic state, reported by other investigators who have
also evaluated the immunocompetence of cervical
cancer patients [33], has been attributed to the com-
pounded negative effects of tumor-induced immunomo-
dulation with those resulting from radiation and
chemotherapy [34,35]. Importantly, our in vitro experi-
ments reveal a significant increase of hI-con1-induced
cytotoxicity after the brief incubation of PBL and tumor
cells with IL-2 compared to the cytotoxicity induced by
hI-con1 in the absence of IL-2. IL-2 seems to therefore
enhance the cytotoxic potential of the effector cells. The
administration of low doses of IL-2 might therefore be a
valid therapeutic option in order to increase IDCC in
heavily pretreated cervical carcinoma patients.
Conclusions
In conclusion, high expression of TF in a large number
of cervical carcinomas makes hI-con1 an attractive
agent for immunotherapy of recurrent/refractory cervi-
cal cancer. In this study, we have demonstrated signifi-
cant hI-con1-mediated killing of multiple primary
cervical cancer cell lines regardless of their squamous or
adenocarcinoma histology. hI-con1 might therefore
represent a novel treatment of this aggressive disease
and, potentially, multiple other human tumors overex-
pressing TF.
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